Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/12088
Título
Recommendations for measuring HIV reservoir size in cure-directed clinical trials.
Autor(es)
Abdel-Mohsen, Mohamed | Richman, Douglas | Siliciano, Robert F | Nussenzweig, Michel C | Howell, Bonnie J | Martinez-Picado, Javier | Chomont, Nicolas | Bar, Katharine J | Yu, Xu G | Lichterfeld, Mathias | Alcamí, José ISCIII | Hazuda, Daria | Bushman, Frederic | Siliciano, Janet D | Betts, Michael R | Spivak, Adam M | Planelles, Vicente | Hahn, Beatrice H | Smith, Davey M | Ho, Ya-Chi | Gaebler, Christian | Paiardini, Mirko | Li, Qingsheng | Estes, Jacob D | Hope, Thomas J | Kostman, Jay | Mounzer, Karam | Caskey, Marina | Fox, Lawrence | Frank, Ian | Riley, James L | Tebas, Pablo | Montaner, Luis J | Buzon, Maria J
Fecha de publicación
2020
Cita
Nat Med . 2020 Sep;26(9):1339-1350.
Idioma
Inglés
Tipo de documento
journal article
Resumen
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.
Palabras clave
HIV latency | HIV reservoirs | Viral measurements | HIV Cure | HIV persistence | Replication-competent HIV
MESH
Anti-Retroviral Agents | CD4-Positive T-Lymphocytes | Clinical Trials as Topic | Disease Reservoirs | HIV Infections | HIV-1 | Humans | Mass Screening | Viral Load | Virus Latency
Versión en línea
DOI
Aparece en las colecciones